Old Mission Capital’s Oasmia Pharmaceutical AB OASM Stock Holding History

Old Mission Capital’s Portfolio OASM Stock Details OASM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,431	Closed	-$24K	–	361
2019 Q1	$24K	Buy	+10,431	New	+$28.6K	﹤0.01%	196
2018 Q3	–	Sell	-16,147	Closed	-$21K	–	359
2018 Q2	$21K	Buy	+16,147	New	+$23.5K	﹤0.01%	257
2017 Q4	–	Sell	-16,919	Closed	-$18K	–	535
2017 Q3	$18K	Buy	+16,919	New	+$17.5K	﹤0.01%	328

Other funds holding OASM

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Old Mission Capital's OASM Position: Q2 2019 in Review

Old Mission Capital sold out of Oasmia Pharmaceutical AB (OASM) in Q2 2019, closing a stake of 10,431 shares — an estimated $24K sold.

Old Mission Capital first reported a position in OASM in Q3 2017 and held it in 3 quarters. The position peaked at $24K in Q1 2019. 4 funds tracked by Wall St. Rank hold OASM as of Q2 2019.

Old Mission Capital reported no remaining Oasmia Pharmaceutical AB position as of Q2 2019 after selling out during the quarter.
Old Mission Capital sold 10,431 Oasmia Pharmaceutical AB shares in Q2 2019, an estimated $24K.
Old Mission Capital first reported a position in Oasmia Pharmaceutical AB in Q3 2017 and held it in 3 quarters.
Old Mission Capital's Oasmia Pharmaceutical AB position peaked at $24K in Q1 2019.
4 funds tracked by Wall St. Rank held Oasmia Pharmaceutical AB as of Q2 2019.

Based on Old Mission Capital's 13F filing for Q2 2019, filed 14 Aug 2019.